Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 14/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989365 | 1.00 | CASP1 (0.48) | CASP1SLC17A5MDM4TP53ALDH1A1 | |
| SCHEMBL14063770 | 0.92 | SLC17A5 (0.43) | CASP1SLC17A5MDM4TP53ALDH1A1 | |
| SCHEMBL19888241 | 0.87 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL14063754 | 0.85 | PPARA (0.58) | CASP1SLC17A5MDM4TP53PPARG | |
| SCHEMBL17633384 | 0.85 | SLC17A5 (0.49) | CASP1SLC17A5MDM4TP53CASP3 | |
| SCHEMBL13716717 | 0.84 | SLC17A5 (0.48) | CASP1SLC17A5MDM4TP53CASP3 | |
| SCHEMBL12707588 | 0.83 | SLC17A5 (0.47) | SLC17A5MDM4TP53PPARGPPARA | |
| SCHEMBL2399667 | 0.83 | SLC17A5 (0.47) | SLC17A5MDM4TP53PPARGPPARA | |
| SCHEMBL28259215 | 0.83 | MDM4 (0.50) | CASP1SLC17A5MDM4TP53CASP3 | |
| SCHEMBL28259217 | 0.83 | MDM4 (0.50) | CASP1SLC17A5MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931083-A4 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | HARVARD COLLEGE (US) | 2000-05-24 | — | — | EP | claimed |
| EP-0931083-A1 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998012198-A1 | PROCESS FOR PRODUCING ECTEINASCIDIN COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-03-26 | — | — | WO | claimed |
| US-12122784-B2 | Preparation method for ecteinascidin compound and intermediate thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-10-22 | — | — | US | disclosed |
| EP-3842438-B1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | BRIGHTGENE BIO MEDICAL TECH CO LTD (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-111518110-B | Preparation method of ecteinascidin compound and intermediate thereof | 博瑞生物医药（苏州）股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20210355132-A1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | UNIVERSITÉ PARIS CITÉ (FR) | 2021-11-18 | — | — | US | disclosed |
| EP-3842438-A1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | Bright Gene Bio-Medical Technology Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-111518110-A | Preparation method of ecteinascidin compound and intermediate thereof | 博瑞生物医药（苏州）股份有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020155613-A1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | 博瑞生物医药（苏州）股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355132-A1 | PREPARATION METHOD FOR ECTEINASCIDIN COMPOUND AND INTERMEDIATE THEREOF | TMED9, EMD, ENTPD8 | CASP1 3200/4885SLC17A5 808/4885MDM4 2890/4885 |
| US-12122784-B2 | Preparation method for ecteinascidin compound and intermediate thereof | TMED9, EMD, ENTPD8 | CASP1 3200/4885SLC17A5 808/4885MDM4 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.